How Fast Can the FDA Bring AI to its Labs?
The Food and Drug Administration on Thursday announced what it called an aggressive agency-wide artificial intelligence adoption timeline, as well as a new AI tool to help scientists spend less time on tedious, repetitive tasks that can slow the review process.
The FDA made the announcement in statement about “an aggressive timeline to scale use of artificial intelligence internally across all FDA centers by June 30, 2025, following the completion of a new generative AI pilot for scientific reviewers.”
The FDA said it plans full AI integration with FDA’s internal data platforms. “I was blown away by the success of our first AI-assisted scientific review pilot. We need to value our scientists’ time and reduce the amount of non-productive busywork that has historically consumed much of the review process,” FDA Commissioner Dr. Martin A. Makary said in a statement. “The agency-wide deployment of these capabilities holds tremendous promise in accelerating the review time for new therapies.”
Excerpted from yahoo! news
